14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IDEV vs GNTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, iShares Core MSCI International Developed Markets ETF (IDEV) captures the overall head-to-head institutional edge over Genenta Science S.p.A. (GNTA) on higher Unified Composite conviction (56.4/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow), while GNTA wins 2–1 across the 6-pillar growth and valuation breakdown. IDEV trades at $88.40 (N/M Forward P/E, N/A operating margin) versus GNTA at $0.98 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: IDEV earns the overall head-to-head edge with a stronger Unified Composite Score (56.4/100 HOLD vs. GNTA 35.3/100 SELL) and 0.94β · 19% Vol risk profile, whereas GNTA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: IDEV is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.1); meanwhile GNTA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IDEV vs GNTA. Trailing 12-month operating profitability (IDEV N/A vs GNTA 0.0%) and valuation multiples (IDEV N/M vs GNTA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Conglomerates value chain with $39.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IDEV vs GNTA Key Questions & Quantitative Answers
As of Nov 16, 2026, iShares Core MSCI International Developed Markets ETF (IDEV) captures the overall head-to-head institutional edge over Genenta Science S.p.A. (GNTA) on higher Unified Composite conviction (56.4/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow), while GNTA wins 2–1 across the 6-pillar growth and valuation breakdown. IDEV trades at $88.40 (N/M Forward P/E, N/A operating margin) versus GNTA at $0.98 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IDEV earns the overall head-to-head edge with a stronger Unified Composite Score (56.4/100 HOLD vs. GNTA 35.3/100 SELL) and 0.94β · 19% Vol risk profile, whereas GNTA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IDEV is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.1); meanwhile GNTA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GNTA leads the Growth & Scale pillar: IDEV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GNTA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IDEV generates N/A in USD-normalized revenue versus N/A for GNTA. In operating R&D and SG&A reinvestment, IDEV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNTA.
IDEV and GNTA trade at balanced relative valuation multiples. IDEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GNTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IDEV (N/A ROE) versus GNTA (-38.0% ROE) capital efficiency.
In options market volatility and institutional positioning, IDEV carries 26.3% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 19% Vol realized risk). By comparison, GNTA carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 132% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.